openPR Logo
Press release

Chronic Idiopathic Constipation Market Research Report 2024

04-19-2017 04:57 PM CET | Health & Medicine

Press release from: Transparency Market Research

Chronic Idiopathic Constipation Market Research Report 2024

Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation is unclear or unknown and not because of underlying illness or medication. As cause of constipation is unclear, it is called idiopathic constipation. Often chronic idiopathic constipation is indicated with multiple symptoms. The repeatedly occurring most common symptoms include abdominal discomfort, bloating, gas pain, incomplete evacuation, hard stool, and straining at the time of bowel movement.

Get Sample Copy of this Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20537

Chronic idiopathic constipation occurs without an identifiable cause. Several factors contribute to constipation including change in water balance and motility in colon. The rate at which muscles in colon contract to help pass through the stool is referred as motility. If colon absorbs more water, the stool can be hard, dry, and difficult to pass. The infrequent bowel movement could be due to dry, hard stool leading to chronic idiopathic constipation. If motility is slower down, the stool movement can be difficult to pass which results in infrequent bowel movement. This slow movement results in more water absorption and leads to hard, dry stool. A survey found chronic idiopathic constipation common in 56% women, 44% men. It has been observed more common in adult aged or older people. Out of patients suffering from chronic idiopathic constipation only 12% are medically diagnosed and 40% are actively seeking treatment. Increasing incidence, prevalence, and growing awareness can be considered the major factors driving the global chronic idiopathic constipation treatment market. Rising prescription opioid consumption, increasing geriatric population, rising health care expenditure, launch of targeted medicines, and growing awareness are likely to drive the chronic idiopathic constipation treatment market during the forecast period.

The global chronic idiopathic constipation treatment market has been segmented based on type, type of administration, region, and distribution channel. In terms of type, the market has been segmented into pharmacological treatment and non-pharmacological treatment. Pharmacological treatment consists of stool softener, laxatives, bulk forming agents, emollients, osmotic agents, chloride channel activators, and others. Based on type of administration, the global chronic idiopathic constipation treatment market has been categorized into oral and parenteral. In terms of distribution channel, the market has been divided into independent pharmacies, drug stores, and hospital pharmacies. The data obtained from the National Center for Biotechnology Information revealed that 4 million people in the U.S. have frequent constipation, corresponding to prevalence of 2%. The laxatives and stool softeners segments are expected to account for major share of the global chronic constipation market during the forecast period in comparison to other class of drugs.

Geographically, the global chronic idiopathic constipation treatment market has been segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to hold major share of the chronic idiopathic constipation treatment market owing to significant percentage of population suffering from CIC. Europe was the second largest market for chronic idiopathic constipation treatment due to high prevalence rate. India, China, and Japan are likely to fuel the growth of the global chronic idiopathic constipation market in Asia Pacific. Abbott Gut-Health Survey reported that 14% people in India suffer from constipation. Mexico and Brazil are the high potential growth markets in Latin America because of improvement of medical infrastructure.

Major players in the global chronic idiopathic constipation treatment market include Boehringer Ingelheim GmbH, Bayer AG, C. B. Fleet Company, Inc., Daewoong Co. Ltd., Synergy Pharmaceuticals, Inc., Actavis, Ironwood Pharmaceuticals, Cosmo Pharmaceuticals, and Sucampo Pharmaceuticals, Inc.

View Report @ http://www.transparencymarketresearch.com/chronic-idiopathic-constipation-treatment-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Idiopathic Constipation Market Research Report 2024 here

News-ID: 507856 • Views:

More Releases from Transparency Market Research

Smart Food Packaging Market Outlook 2032: Expected to Reach US$ 8.0 Billion by 2032, Growing at a CAGR of 5.8% from 2024
Smart Food Packaging Market Outlook 2032: Expected to Reach US$ 8.0 Billion by 2 …
The global smart food packaging market (スマート食品包装市場) was valued at US$ 4.8 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2032, reaching a valuation of US$ 8.0 billion by 2032. Download Sample Report Copy Here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85208&utm_source=OpenPR_Sandeep&utm_medium=OpenPR Analyst Viewpoint The introduction of novel food technologies due to rising consumer and industrial demand for safe and protective food packaging is a key
Retail Ready Packaging Market Outlook 2032: Projected to Reach US$ 102.2 Billion by 2032, Growing at a CAGR of 2.4% from 2024
Retail Ready Packaging Market Outlook 2032: Projected to Reach US$ 102.2 Billion …
The global retail ready packaging market (소매용 포장 시장) was valued at US$ 81.4 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 2.4% from 2024 to 2032, reaching US$ 102.2 billion by the end of 2032. Download Sample Report Copy Here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14105&utm_source=OpenPR_Sandeep&utm_medium=OpenPR Analyst Viewpoint The increase in the popularity of die cut display containers is a key factor driving the retail ready packaging market.
Packaging Automation Market Outlook 2032: Expected to Reach US$ 52.2 Billion by 2032, Growing at a CAGR of 3.7% from 2024
Packaging Automation Market Outlook 2032: Expected to Reach US$ 52.2 Billion by …
The global packaging automation market (包装自動化市場) was valued at US$ 37.5 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2032, reaching US$ 52.2 billion by the end of 2032. Download Sample Report Copy Here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14096&utm_source=OpenPR_Sandeep&utm_medium=OpenPR Analyst Viewpoint The increase in efficiency through advanced packaging technologies is propelling the packaging automation market size. Automation improves efficiency, reduces errors, and enhances the
Brain Cancer Diagnostics Market Worth USD 2.5 Bn, at a 5.9% CAGR By 2031 - Trans …
Brain cancer remains one of the most challenging and complex malignancies to diagnose and treat. Advances in diagnostic technologies and methods are crucial for early detection and effective management of brain tumors. The global brain cancer diagnostics market, valued at approximately USD 1.5 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 5.9% from 2023 to 2031, reaching more than USD 2.5 billion by

All 5 Releases


More Releases for Chronic

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Reviewed, …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney Disease (Chronic Renal Failure). Report includes an overview of trial numbers and
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market Res …
Latest industry research report on: Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts GlobalData's clinical trial report, Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the
Boot chronic pain
For immediate release Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue. We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them
11-10-2016 | Health & Medicine
MRR.biz
Global Chronic, Acute, And Neuropathic Pain Market: Opioids To Remain Most Value …
The research report, titled “Frontier Pharma: Chronic, Acute And Neuropathic Pain - GPCR And Nerve Growth Factor-Based Therapies Offer Strong Potential In Difficult-To-Treat Subtypes,” analyzes the historical as well as the existing performance of this market, emphasizing specifically on various types of therapies applied to treat chronic, acute, and neuropathic pain. According to this 68-page study, the worldwide market for chronic, acute, and neuropathic pain has been observing a significant
Targeting chronic pain
With the support of the Austrian Science Fund FWF, the neurophysiologist Ruth Drdla-Schutting is investigating the role astrocytes play in the genesis of chronic pain. With the help of innovative gene technology (DREADDs), scientists are tailoring treatment specifically to these cells that are the most numerous found in the central nervous system. Pain is an important protection system of the human body. But when it becomes chronic, as it frequently